RADIMMUNE THERAPEUTICS
Radimmune Therapeutics is an early-stage biotechnology company that pioneers innovative therapies. It develops antibody-targeted radiation therapeutics, also known as radioimmunotherapy and liquid radiation. An alpha-emitting and/or beta-emitting radioisotope is guided to a universal target antigen. Radimmune has developed proprietary antibodies targeting extracellular accumulations of, normally, intracellular substances. Since its inception, the Radimmune Therapeutics has been driven by the belief that additional tools are needed for the fight against cancer. To that end, Radimmune Therapeutics has developed proprietary technology and platform focused on the most challenging to treat cancers. It is based in Burlingame, California.
RADIMMUNE THERAPEUTICS
Industry:
Biotechnology Medical Therapeutics
Founded:
2016-01-01
Address:
Burlingame, California, United States
Country:
United States
Website Url:
http://www.radimmune.com
Total Employee:
1+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
13.56 M USD
Technology used in webpage:
Google Apps For Business GoDaddy Email Ninja Forms
Similar Organizations
Remix Therapeutics
Remix Therapeutics is a biotechnology company.
Tango Therapeutics
Tango Therapeutics is a biotechnology company that is developing next generation cancer therapies.
Current Employees Featured
Founder
Official Site Inspections
http://www.radimmune.com Semrush global rank: 5.45 M Semrush visits lastest month: 1.56 K
- Host name: ec2-13-223-25-84.compute-1.amazonaws.com
- IP address: 13.223.25.84
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Radimmune Therapeutics"
Radimmune Therapeutics - Crunchbase Company Profile & Funding
Radimmune Therapeutics is an early-stage biotechnology company that pioneers innovative therapies. It develops antibody-targeted radiation therapeutics, also known as …See details»
RadImmune Company Profile 2024: Valuation, Funding
Information on valuation, funding, cap tables, investors, and executives for RadImmune. Use the PitchBook Platform to explore the full profile.See details»
RadImmune - VentureRadar
Website: http://radimmune.com/ Develops antibody-targeted radiation therapeutics, including radioimmunotherapy and liquid radiation, using proprietary antibodies to target extracellular …See details»
RadImmune Therapeutics - Products, Competitors, Financials, …
RadImmune Therapeutics is a start up biotechnology company with a multidisciplinary management team that is committed to fostering research and development in molecular …See details»
RADIMMUNE THERAPEUTICS, INC. - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for RADIMMUNE THERAPEUTICS, INC. of San Mateo, CA. Get the latest business insights from Dun & …See details»
RadImmune - Company Profile - Tracxn
Oct 31, 2024 · RadImmune Therapeutics is a biotech startup developing novel treatments for cancer through their expertise in molecular targeted radiotherapy (radio immunotherapy). The …See details»
Radimmune - Overview, News & Similar companies | ZoomInfo.com
Nov 15, 2018 · Radimmune contact info: Phone number: (914) 332-5393 Website: www.radimmune.com What does Radimmune do? Radimmune is developing antibody …See details»
Radimmune Therapeutics - Contacts, Employees, Board Members, …
Radimmune Therapeutics has 3 current employee profiles, including President, CEO, and Board Member Steven Deitcher. Radimmune Therapeutics is an early stage biotechnology company …See details»
Steven Deitcher - President, CEO, and Board Member
Steven R. Deitcher is the President, CEO, and Board Member of Radimmune Therapeutics. He attended Northwestern University - The Feinberg School of Medicine.See details»
Advancing Targeted Radionuclide Therapy Through the National …
May 15, 2018 · RadImmune, Inc., received phase I funding to develop a radioimmunotherapy for metastatic melanoma based on a novel IgG to melanin. RadImmune previously completed a …See details»
Radimmune Therapeutics Selected Goodwin Biotechnology for …
Nov 15, 2018 · RadImmune Therapeutics has developed a novel therapeutic approach leveraging its unique and proprietary monoclonal antibody (mAb) platform as a Radioimmunotherapeutic …See details»
A randomized phase II study of radiation induced immune boost …
Dec 19, 2015 · Ionizing radiation can induce a variety of immune responses. The goal of this randomized trial is to assess if a preoperative single fraction low dose radiation is able to …See details»
Evaluating the Combination of Radioimmunotherapy and …
Jan 24, 2020 · We conclude that Cloudman S91 murine melanoma in DBA/2 mouse is a suitable model to evaluate combination of immunotherapy of melanoma with tangentially targeted …See details»
Mechanistic Insights into Synergy between Melanin-Targeting ...
Nov 18, 2020 · Immune checkpoint blockade (ICB) has demonstrated clinical success with approved drugs in cohorts of patients with metastatic melanoma and targeted radionuclide …See details»
Lintuzumab-Ac225, a CD33-Directed Antibody Radiotherapy, …
Nov 2, 2023 · Actimab-A, an anti-CD33 antibody conjugated with Actinium-225 (Ac-225) alpha particle-emitting radionuclide (lintuzumab-Ac225), has demonstrated promising therapeutic …See details»
A randomized phase II study of radiation induced immune boost …
Dec 19, 2015 · Radiation will be delivered by external beam radiotherapy using 3D radiotherapy or intensity-modulated radiation technique (IMRT) 7 days prior to surgical resection. The …See details»
Comparative Radioimmunotherapy of Experimental Melanoma …
Jul 18, 2019 · We performed comparative radioimmunotherapy (RIT) of experimental B16-F10 melanoma with novel humanized IgG to melanin h8C3 labeled with a beta emitter, 177 Lu, and …See details»
ESMO Congress 2022 | OncologyPRO
The RAD51 test can identify Homologous Recombination Repair (HRR)-deficient (HRD) tumors and may add prognostic value in this subset of patients, potentially guiding post-neoadjuvant …See details»
Radimmune Therapeutics, Inc. Company Profile | San Mateo, CA ...
Find company research, competitor information, contact details & financial data for Radimmune Therapeutics, Inc. of San Mateo, CA. Get the latest business insights from Dun & Bradstreet.See details»
146P HRD/TIL-low high-risk breast cancer is characterized by good ...
PDF | On Sep 1, 2022, B. Pellegrino and others published 146P HRD/TIL-low high-risk breast cancer is characterized by good prognosis (the RADIMMUNE trial) | Find, read and cite all the …See details»